HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chanelle McCoy Health Claims Leadership In UK CBD Market Following FSA List Inclusion

Executive Summary

Irish synthetic cannabidiol supplier and Pureis brand owner Chanelle McCoy Health says early inclusion on the UK food regulator's list of validated CBD products sets the company apart from the competition. Meanwhile, an additional CBD supplier - Rokshaw - has also been added. 

You may also be interested in...

First UK CBD Novel Food Authorizations Not Expected Until 2024 At The Earliest

Summer 2024 is the earliest that the UK Food Standards Agency expects CBD applications to be fully authorized, according to its most recent board meeting. However, even this belated deadline could slip if the Home Office complicates matters or if the FSA is flooded with other regulated product applications. Meanwhile, the official CBD list has swelled to over 12,000 products, with thousands now validated and a few “removed” by mistake. 

Unlisted CBD Products Could Soon Be Removed From UK Shelves, Says FSA

The Food Standards Agency's list of validated and on-hold CBD products will soon see a significant update, says CEO Emily Miles. Those not on the list will be targeted for removal.

Two More Suppliers Added To UK FSA’s CBD List, More Soon To Follow?

Two more CBD suppliers have made it onto the UK FSA's list of validated novel food applications, bringing the total up to 78 products. More may follow next week, according to Canna Consultants’ Stephen Oliver.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts